Articles related to ANTISEIZURE MEDICATIONS

The NAUTILUS trial met its primary safety endpoint for responsive centromedian thalamic stimulation in drug-resistant idiopathic generalized epilepsy. The prespecified primary effectiveness endpoint was not significant, while post hoc and 18-month outcomes showed sustained seizure reductions.

Most newly diagnosed focal epilepsy patients required more than a year and more than one antiseizure medication to reach seizure freedom in a multicenter cohort.

The study objectives were to compare the outcomes of 6-year-old children of women with epilepsy (WWE) vs those of healthy pregnant women (HW), and to assess the association of outcomes to third-trimester antiseizure medications (ASM) exposures.

After adjustment for demographic and clinical factors, cenobamate was associated with statistically significant higher odds of achieving a 50% or greater reduction in seizure frequency at 6 months vs all three comparators.

“Too many neurons go astray, and that’s when you get amyloid-beta production. And then it’s tau, and then it’s dead cells, then dementia — and then it’s too late.” — Jeffrey Savas, Northwestern University

Lamotrigine was not associated with an increased risk of ventricular arrhythmia and sudden cardiac arrest compared with levetiracetam, including among those with underlying heart disease.